

AB-116U

10/081,820
RECEIVED
CENTRAL FAX CENTER
MAR 06 2007

REMARKS

This is a full and timely response to the final Official Action mailed October 6, 2006. Reconsideration of the application in light of the above amendment and the following remarks is respectfully requested. A request for a two (2) month extension of time and the requisite fee accompany this paper.

Request for Continued Examination:

Applicant hereby requests Continued Examination for this application and entry and consideration of this amendment consequent thereto.

Claim Status:

By the foregoing amendment, claim 37 has been withdrawn without prejudice or disclaimer. No claims have been amended and no new claims have been added. Applicant does not disclaim the subject matter of the withdrawn claim and reserves the right to file any number of continuation or divisional applications to the withdrawn claim or to any other subject matter described in the present application. Claims 6, 7, 9-13, 17-35, 39 and 40 were canceled previously without prejudice or disclaimer. Thus, claims 1-5, 8, 14-16, 36, 38, and 41 are currently pending for further action.

Claim Rejections ~ 35 U.S.C. § 103:

Claims 1-5, 8, 14-16, 36, 38, and 41 were rejected as unpatentable under 35 U.S.C. § 103(a) in view of U.S. Patent No. 6,164,284 to Schulman et al. ("Schulman-1"), U.S. Patent No.

AB-116U

10/081,820

5,312,439 to Loeb ("Loeb"), or U.S. Patent No. 5,324,316 to Schulman et al. ("Schulman-2"), each in view of U.S. Patent No. 5,928,272 to Adkins et al. ("Adkins"), U.S. Patent No. 5,540,730 to Terry, Jr. et al. ("Terry-1"), U.S. Patent No. 5,330,507 to Schwartz et al. ("Schwartz"), U.S. Patent No. 5,335,657 to Terry, Jr. et al. ("Terry-2"), or U.S. Patent No. 5,330,515 to Rutecki et al. ("Rutecki"). This rejection is respectfully traversed for at least the following reasons.

Claim 1 recites:

A method of treating a patient with at least one of epilepsy, a metabolic disorder, a mood disorder, an anxiety disorder, chronic pain, a gastrointestinal disorder, hypertension, a cardiac disorder, a psychotic disorder, a cognitive disorder, dementia, an eating disorder, obesity, a sleep disorder, an endocrine disorder, a movement disorder, and headache, the method comprising:

providing at least one leadless stimulator having at least two electrodes disposed thereon;

implanting the at least one stimulator adjacent to at least one portion of the patient's vagus nerve;

generating stimulation pulses with the stimulator in accordance with one or more stimulation parameters; and

delivering the stimulation pulses to nerve fibers adjacent to at least one portion of the vagus nerve.

(emphasis added).

Claim 38 recites similar subject matter.

In Applicant's previous response of July 17, 2006, Applicant presented a number of arguments asserting the allowability of claims 1 and 38 and their respective dependent claims. However, in the recent Office Action, the Examiner addressed only one of those arguments and, in so doing, completely mischaracterized said argument. All of the other arguments made by Applicant were completely ignored as the Examiner repeated verbatim the position taken in the Office Action of October 6, 2005.

AB-116U

10/081,820

To illustrate, the Examiner stated in the recent Office Action that “Applicant argues that the combination of references applied in the rejection of the claims requiring a leadless stimulator would not be appropriate because the secondary references use leads for sensors.” (page 4, Office Action of 10/6/06). Applicant wonders where this conclusion comes from. A review of Applicant’s previous response of July 17, 2006 reveals no such argument. Applicant assumes that the Examiner was addressing the paragraphs that bridge pages 8-9 of Applicant’s previous response. However, in so doing, the Examiner completely mischaracterized and misinterpreted Applicant’s arguments contained therein.

Hence, the Examiner’s entire “Response to Arguments” section regarding the use of a sensor in combination with a stimulator to treat a headache is entirely irrelevant to the subject matter recited in independent claims 1 and 38. These claims recite stimulating a patient’s vagus nerve with a *leadless* implantable stimulator in order to treat epilepsy, a metabolic disorder, a mood disorder, an anxiety disorder, chronic pain, a gastrointestinal disorder, hypertension, a cardiac disorder, a psychotic disorder, a cognitive disorder, dementia, an eating disorder, obesity, a sleep disorder, an endocrine disorder, a movement disorder, or headache. The cited prior art, even with the addition of Schulman-1, fails to teach or suggest stimulating a patient’s vagus nerve with a *leadless* implantable stimulator in order to treat any of the claimed medical conditions.

Moreover, by repeating verbatim the arguments made in the Office Action of October 6, 2005, the Examiner has not met his burden of proof in establishing the obviousness rejection. An Examiner must provide specific reasons to support an obviousness rejection. *Ex parte Humphreys*, 24 USPQ2d 1255. The Examiner has not provided specific reasons in this or any

AB-116U

10/081,820

other Office Action as to why any of the references, alone or in combination, would render obvious the claimed methods of stimulating the vagus nerve with a leadless implantable stimulator.

Hence, Applicant reasserts herein that the combination of Schulman-1, Loeb, or Schulman-2 with Adkins, Terry-1, Schwartz, Terry-2, or Rutecki fails to teach or suggest stimulating a patient's vagus nerve with a *leadless* implantable stimulator in order to treat epilepsy, a metabolic disorder, a mood disorder, an anxiety disorder, chronic pain, a gastrointestinal disorder, hypertension, a cardiac disorder, a psychotic disorder, a cognitive disorder, dementia, an eating disorder, obesity, a sleep disorder, an endocrine disorder, a movement disorder, or headache for the following reasons:

A. Prior art does not teach claimed invention or motivate modification; rather, prior art teaches away from the claimed invention

According to the Office Action, the teachings of Schulman-1, Loeb, or Schulman-2 with Adkins, Terry-1, Schwartz, Terry-2, or Rutecki may be combined to render obvious the method of stimulating the vagus nerve with a leadless implantable stimulator as recited in claim 1. Applicant respectfully disagrees. Combining elements "in a manner that reconstructs the applicant's invention only, with the benefit of hindsight, is insufficient to present a *prima facie* case of obviousness. There must be some reason, suggestion, or motivation found in the prior art whereby a person of ordinary skill in the field of the invention would make the combination. That knowledge cannot come from the applicant's invention itself." *In re Oetiker*, 24 USPQ2d 1443, 1447 (Fed. Cir. 1992) (citations omitted).

AB-116U

10/081,820

Applicant respectfully submits that none of the cited prior art provides a reason, suggestion, or motivation to stimulate the vagus nerve with a *leadless* implantable stimulator. For example, although Loeb and the Schulman references disclose a leadless microstimulator, none of the cited prior art teaches, suggests, or gives a motivation to use such a microstimulator to stimulate the vagus nerve. Rather, each of the cited prior art references specifically teaches using a stimulating device with a *lead* to apply electrical stimulation to the vagus nerve. (See, e.g., Adkins, col. 2, lines 28-52; Terry-1, col. 4, lines 5-26; Terry-2, col. 8, lines 2-5; Schwartz, col. 5, lines 13-39; or Rutecki col. 8, lines 42-64).

Moreover, the cited prior art teaches away from stimulating the vagus nerve with a leadless implantable stimulator. For example, Adkins discloses a stimulating device configured to stimulate the vagus nerve in accordance with cardiac activity as sensed by one or more sensing electrodes. (Adkins, col. 4, lines 24-37). These sensing electrodes are "located at predetermined spaced-apart points along the exterior of the device case, and not on a separate lead or leads external to the case. *As a result, the only lead required to be implanted in the patient is the lead associated with the electrode array to be implanted on the vagus (or other cranial) nerve for stimulation thereof.*" (Adkins, col. 4, lines 41-47, emphasis added). The leadless electrodes disclosed in Adkins are *only* configured to sense cardiac activity. There is no reason, suggestion, or motivation given in Adkins to also use the leadless electrodes to stimulate the vagus nerve. Rather, Adkins expressly requires the use of a lead for stimulation thereof, despite the fact that the Adkins application was filed approximately four years after both Loeb and Schulman-2 issued as patents.

AB-116U

10/081,820

Hence, the combination of Schulman-1, Loeb, or Schulman-2 with Adkins, Terry-1, Schwartz, Terry-2, or Rutecki fails to suggest the desirability of stimulating the vagus nerve with a leadless stimulator as recited in claims 1 and 38. Although the Office Action concludes that the combination of the cited prior art makes obvious the claimed invention, it has not shown that there is any teaching or suggestion in any of the references, or in the prior art as a whole, that would lead one with ordinary skill in the art to make the combination. "The Commissioner bears the burden of *showing* that such knowledge provided some teaching, suggestion, or motivation to make the particular combination that was made by the applicant." M.P.E.P § 2142; *In re Raynes* 28 USPQ2d 1630, 1632 (Fed. Cir. 1993) (citations omitted; emphasis added). Given the contrary teachings of the prior art (e.g., Adkins), one of skill in the art would certainly not have found it obvious to combine the teachings of Schulman-1, Loeb, or Schulman-2 with Adkins, Terry-1, Schwartz, Terry-2, or Rutecki as proposed in the recent Office Action. Consequently, under *Graham v. John Deere Co.*, 383 U.S. 1 (1966), the proposed combination of Schulman-1, Loeb, or Schulman-2 with Adkins, Terry-1, Schwartz, Terry-2, or Rutecki is improper and insufficient to demonstrate a *prima facie* case of obviousness with respect to the subject matter of claims 1 and 38.

B. A reasonable expectation of success is not found in the prior art; obvious to try is an improper standard

The Office Action has failed to show a reasonable expectation of success in the prior art with regard to stimulating the vagus nerve with a leadless implantable stimulator. A reasonable

AB-116U

10/081,820

expectation of success is the standard with which obviousness is determined, and as MPEP § 2142 clarifies:

[t]he reasonable expectation of success must be found in the prior art, and not based on applicant's disclosure. *In re Vaeck*, 947 F.2d 488, 20 USPQ2d 1438 (Fed. Cir. 1991).

Using the CCPA evaluation of a prima facie case of obviousness, first, a determination is made whether "the references by themselves...suggest doing what appellants have done." *In re Clinton*, 527 F.2d 1226, 1228, 118 USPQ 365, 367 (CCPA 1976).

The CCPA next considered whether a person of ordinary skill in the art would have had a basis for the required reasonable expectation of success: "Obviousness does not require absolute predictability but a reasonable expectation of success is necessary." *Id.*, 527 F.2d at 1228, 118 USPQ at 367. This requirement that there be a reasonable expectation of success follows from the court's requirement in *In re Tomlinson*, 150 USPQ 623 (CCPA 1966), that the prior art or surrounding circumstances must have made any proposed modification or changes in the prior art obvious to do rather than obvious to try. The court in *Tomlinson* stated:

...we think that there is usually an element of 'obviousness to try' in any research endeavor...and that patentability determinations based on that as the test would not only be contrary to the statute but would result in a marked deterioration of the entire patent system as an incentive to invest in those efforts and attempts which go by the name 'research'.

Id. at 626. Thus, "whether a particular combination might be 'obvious to try' is not a legitimate test of *patentability*." *In re Fine*, 837 F.2d 1071 (Fed. Cir. 1988) (citations omitted; emphasis added).

As further described in MPEP § 2145, an "obvious to try" standard has been improperly applied to 35 U.S.C. 103, mainly in two situations: suggesting that it is obvious 1) to "try each of

AB-116U

10/081,820

numerous possible choices until one possibly arrived at a successful result, where the prior art gave...no direction as to which of many possible choices is likely to be successful” or

2) “to explore a new technology or general approach that seemed to be a promising field of experimentation, where the prior art gave only general guidance as to the particular form of the claimed invention or how to achieve it. *In re O’Farrell*, 853 F.2d 894, 903, 7 USPQ2d 1673, 1681 (Fed. Cir. 1988) (citations omitted).”

The assertion in the Office Action that it would have been obvious to one of ordinary skill in the art to take the Schulman-1, Loeb, or Schulman-2 device and substitute it for one of the leadless devices in Adkins, Terry-1, Schwartz, Terry-2, or Rutecki is an unsupported conclusion. Hence, although the Loeb and Schulman devices may be implanted in any part of the body, the cited prior art fails to give any direction as to how to achieve vagus nerve stimulation with a leadless stimulator, and is further evidenced by the lack of content directed to leadless stimulators disclosed in Adkins, Terry-1, Schwartz, Terry-2, and Rutecki.

Double Patenting:

Claims 1-5, 8, 14-16, 36, 38, and 41 were rejected as unpatentable under the judicially created doctrine of obviousness-type double patenting in view of U.S. Patent No. 6,735,475 to Whitehurst et al. (“Whitehurst”) considered in light of U.S. Patent No. 5,330,515 to Rutecki et al. (“Rutecki”). Without necessarily agreeing with or acquiescing to the Examiner’s reasoning, Applicant has submitted herewith a Terminal Disclaimer to overcome this rejection. The Terminal Disclaimer submitted herewith replaces the Terminal Disclaimer previously filed,

AB-116U

10/081,820


which incorrectly identified the Whitehurst patent. Therefore, the double patent rejection should now be reconsidered and withdrawn.

Conclusion:

For the foregoing reasons, the present application is thought to be clearly in condition for allowance. Accordingly, favorable reconsideration of the application in light of these remarks is courteously solicited. If any fees are owed in connection with this paper which have not been elsewhere authorized, authorization is hereby given to charge those fees to Deposit Account 18-0013 in the name of Rader, Fishman & Grauer PLLC. If the Examiner has any comments or suggestions which could place this application in even better form, the Examiner is requested to telephone the undersigned attorney at the number listed below.

Respectfully submitted,


DATE: March 6, 2007


Travis K. Laird
Registration No. 55,351

Travis K. Laird, Esq.
Rader Fishman & Grauer PLLC
River Park Corporate Center One
10653 S. River Front Parkway, Suite 150
South Jordan, Utah 84095
(801) 572-0185
(801) 572-7666 (fax)

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted to the Patent and Trademark Office facsimile number **571-273-8300** on **March 6, 2007**. Number of Pages: **23**


Rebecca R. Schow